Comparison of Treatment Strategies for Patients With Clinical Stage T1–3/N2 Lung Cancer
| Autor: | Ching-Yuan Cheng, Ya-Fu Cheng, Ching-Hsiung Lin, Wei-Heng Hung, Bing-Yen Wang, Heng-Chung Chen, Sheng-Hao Lin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms Time Factors Multivariate analysis medicine.medical_treatment Kaplan-Meier Estimate Disease Pneumonectomy Internal medicine Adjuvant therapy Humans Medicine Stage (cooking) Lung cancer Neoadjuvant therapy Aged Neoplasm Staging Retrospective Studies business.industry Proportional hazards model Chemoradiotherapy Adjuvant Middle Aged medicine.disease Neoadjuvant Therapy Survival Rate Treatment Outcome Chemotherapy Adjuvant Female business SEER Program |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 18:143-150 |
| ISSN: | 1540-1413 1540-1405 |
| DOI: | 10.6004/jnccn.2019.7353 |
| Popis: | Background: The therapeutic strategies for clinical stage T1–3N2 (cT1–3N2) lung cancer are controversial. For operable tumors, treatment can vary by center, region, and continent. This study aimed to identify the optimal therapeutic method and type of surgical strategy for cT1–3N2 lung cancer. Methods: This retrospective evaluation analyzed the records of 17,954 patients with cT1–3N2 lung cancer treated in 2010 through 2015 from the SEER database. The effects of different therapeutic methods and types of surgical strategies on overall survival (OS) were assessed. Univariate and multivariate analyses were performed using a Cox proportional hazards model. Results: The 5-year OS rates were 27.7% for patients with T1N2 disease, 21.8% for those with T2N2 disease, and 19.9% for T3N2 disease. Neoadjuvant therapy plus operation (OP) plus adjuvant therapy, and OP plus adjuvant therapy, provided better 5-year OS rates than OP alone or concurrent chemoradiotherapy (34.1%, 37.7%, 29.3%, and 16.1%, respectively). In the T1N2, T2N2, and T3N2 groups, lobectomy provided better 5-year OS than pneumonectomy, sublobectomy, and no surgery. Both univariate and multivariate analyses showed that young age, female sex, well-differentiated histologic grade, adenocarcinoma cell type, neoadjuvant and adjuvant therapy, lobectomy, and T1 stage were statistically associated with better 5-year OS rates. Conclusions: In cT1–3N2 lung cancer, multimodal treatments tended to provide better 5-year OS than OP alone or concurrent chemoradiotherapy. In addition, lobectomy was associated with better survival than other operative methods. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|